Opportunity Information: Apply for RFA AG 24 043
The NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award is a National Institutes of Health (NIH) funding opportunity from the National Institute on Aging (NIA) designed to help move promising early-career scientists into industry while advancing product-focused research and development through the Small Business Technology Transfer (STTR) program. Released as RFA-AG-24-043, this discretionary grant uses the R41/R42 mechanism (with clinical trials optional) to support projects that combine two things that are often kept separate: rigorous technology development and structured entrepreneurial career development for the project lead.
At its core, the FOA is meant to create a clear on-ramp for postdoctoral fellows and early-stage researchers who have strong technical and discovery experience and want to build real-world commercialization skills while working inside a small business concern (SBC). The program is intentionally structured so that these early-career investigators can serve as the Principal Investigator/Program Director (PI/PD) on an STTR award, with the small business using grant funds to support their hiring and salary. In practical terms, the award is not only paying for experiments and product development; it is also paying to embed an emerging scientific leader within a company environment where they can learn how to translate research into a viable product and, importantly, establish themselves professionally in the private sector.
A defining feature of REDI within this STTR context is the strong emphasis on entrepreneurial training, mentoring, and career development as a major component of the award rather than an add-on. Applicants are expected to treat entrepreneurship as an integral part of the project plan, meaning the PI/PD is being developed alongside the technology. The FOA is aimed at candidates who may already excel at research but need deliberate exposure to the business-side fundamentals that shape whether innovations make it to patients, customers, or care settings. This can include learning how to assess markets, understand customer needs, navigate intellectual property and regulatory considerations, build business models, and communicate value propositions to partners and funders, all while maintaining scientific momentum on the underlying product.
Because the intention is to facilitate the PI/PD's transition into the small business, the FOA makes it clear that most of the PI/PD's employment must be with the SBC. That requirement reinforces the program's workforce-development purpose: it is not meant to be a primarily academic appointment with occasional industry collaboration, but rather a deliberate shift toward an industry-centered role where product development is the day-to-day focus. As an STTR opportunity, the small business is the applicant organization, and the award supports expanding the company's scientific research staff while moving a defined technology toward commercialization readiness.
Eligibility is limited to small businesses as applicants. Foreign institutions and other non-U.S. entities are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible. However, foreign components, as NIH defines them in the NIH Grants Policy Statement, may be allowed in some cases, which typically means certain project elements can occur abroad if they are well-justified and meet NIH policy requirements, though the applicant organization itself must be eligible and U.S.-based under STTR rules.
In terms of basic opportunity details, the sponsoring agency is NIH/NIA, the assistance listing is CFDA 93.866, the funding instrument is a grant, and the original closing date listed for this announcement was October 26, 2023. The announcement describes the award as using the R41/R42 "Industry Development Award" approach, which aligns with the STTR phased structure (generally corresponding to a feasibility-focused Phase I and a development/expansion Phase II) while emphasizing that the project and the investigator are both being advanced: the company is building a product, and the PI/PD is building the entrepreneurial toolkit and industry experience needed to lead translational work over the long term.Apply for RFA AG 24 043
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R41/R42 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2023-08-15.
- Applicants must submit their applications by 2023-10-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the NIA Research and Entrepreneurial Development Immersion (REDI) Entrepreneurial Small Business Transition Award?
It is a National Institutes of Health (NIH) funding opportunity from the National Institute on Aging (NIA) that supports product-focused research and development through the Small Business Technology Transfer (STTR) program, while also providing structured entrepreneurial career development for the project lead.
Which NIH Institute is offering this opportunity?
The opportunity is offered by the National Institute on Aging (NIA) within NIH.
What is the funding opportunity announcement (FOA) number?
The FOA is RFA-AG-24-043.
What grant mechanism does this opportunity use?
This opportunity uses the R41/R42 mechanism under STTR, described as an "Industry Development Award" approach.
Are clinical trials required under this opportunity?
No. Clinical trials are optional under this announcement.
What is the main purpose of REDI within the STTR context?
The purpose is to combine rigorous technology development with structured entrepreneurial training and career development for the PI/PD, helping move promising early-career scientists into industry while advancing a technology toward commercialization readiness.
Who is this program designed to support?
It is designed to create an on-ramp for postdoctoral fellows and early-stage researchers who have strong technical and discovery experience and want to build commercialization and industry skills while working within a small business concern (SBC).
Can an early-career investigator serve as the PI/PD on this STTR award?
Yes. The program is intentionally structured so early-career investigators can serve as the Principal Investigator/Program Director (PI/PD) on an STTR award.
Who is the applicant organization for this opportunity?
The small business concern (SBC) is the applicant organization under STTR for this opportunity.
How does the award support the PI/PD's transition into industry?
The award can support hiring and salary for the PI/PD through the small business, embedding the emerging scientific leader in a company environment where product development and commercialization-focused work are central.
Is the award only for research experiments and development work?
No. The award supports both product-focused research and development and a major entrepreneurial training and career development component for the PI/PD.
How important is entrepreneurial training in this FOA?
Entrepreneurial training, mentoring, and career development are defining features of REDI in this STTR context and are expected to be treated as an integral part of the project plan rather than an add-on.
What kinds of entrepreneurial skills does the FOA expect the PI/PD to develop?
The FOA describes deliberate exposure to business-side fundamentals such as assessing markets, understanding customer needs, navigating intellectual property and regulatory considerations, building business models, and communicating value propositions to partners and funders, while maintaining progress on the underlying technology.
What does the FOA say about where the PI/PD must be employed?
The FOA emphasizes that most of the PI/PD's employment must be with the small business concern (SBC), reinforcing that the intent is an industry-centered role rather than a primarily academic appointment.
Does this program support workforce development for small businesses?
Yes. As described, it supports expanding a company's scientific research staff while simultaneously helping the PI/PD establish themselves professionally in the private sector.
How does the STTR phased structure relate to this opportunity?
The award aligns with the STTR phased structure, generally corresponding to a feasibility-focused Phase I (R41) and a development/expansion Phase II (R42), while emphasizing advancement of both the technology and the investigator's entrepreneurial readiness.
Who is eligible to apply?
Eligibility is limited to small businesses as applicants.
Are foreign institutions or non-U.S. entities eligible to apply?
No. Foreign institutions and other non-U.S. entities are not eligible to apply.
Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are also not eligible.
Are any foreign components allowed at all?
Foreign components, as NIH defines them in the NIH Grants Policy Statement, may be allowed in some cases. This typically means certain project elements could occur abroad if well-justified and compliant with NIH policy, while the applicant organization itself must still be an eligible U.S.-based small business under STTR rules.
What is the sponsoring agency and assistance listing for this opportunity?
The sponsoring agency is NIH/NIA, and the assistance listing is CFDA 93.866.
What type of funding instrument is used?
The funding instrument is a grant.
What was the original closing date listed for this announcement?
The original closing date listed was October 26, 2023.
What makes this opportunity different from a typical STTR award?
Based on the description provided, a defining difference is that entrepreneurial training and structured career development for the PI/PD are central features of the award, explicitly coupled to the technology development plan to support a real transition of the investigator into an industry environment.
What is the intended day-to-day focus for the PI/PD under this FOA?
The FOA frames the intended role as industry-centered, where product development and commercialization-oriented activities are part of the PI/PD's regular work in the small business setting.
Browse more opportunities from the same category: Health
Next opportunity: 2024 Alumni Engagement Innovation Fund
Previous opportunity: Drug Demand Reduction
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 24 043
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 24 043) also looked into and applied for these:
| Funding Opportunity |
|---|
| VCID Center Without Walls for Understanding and Leveraging Small Vessel Cerebrovascular Disease Mechanisms in ADRD (R01 - Clinical Trial Not Allowed) Apply for RFA NS 24 027 Funding Number: RFA NS 24 027 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| NINDS Clinical Trial Methods in Clinical Neurological Disorders Course (R25 Clinical Trial Not Allowed) Apply for RFA NS 23 030 Funding Number: RFA NS 23 030 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Improving Diagnostic Safety in Ambulatory Care: Strategies and Interventions (R18) Apply for PA 23 290 Funding Number: PA 23 290 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| AHRQ Understanding and Improving Diagnostic Safety in Ambulatory Care: Incidence and Contributing Factors (R01) Apply for PA 23 291 Funding Number: PA 23 291 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) Apply for PAR 23 274 Funding Number: PAR 23 274 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed) Apply for RFA AG 24 046 Funding Number: RFA AG 24 046 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R34 Clinical Trial Optional) Apply for RFA MH 24 162 Funding Number: RFA MH 24 162 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Building Neuroscience Research Infrastructure for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) in Africa (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA AG 24 027 Funding Number: RFA AG 24 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Science for Society (ComPASS): Health Equity Research Hubs (UC2 Clinical Trial Optional) Apply for RFA RM 23 012 Funding Number: RFA RM 23 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Broadening Opportunities for Computational Genomics and Data Science Education (UE5 Clinical Trial Not Allowed) Apply for RFA HG 23 002 Funding Number: RFA HG 23 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Consortium for Economic Research on AD/ADRD Prevention, Treatment, and Care (R01 Clinical Trial Optional) Apply for RFA AG 24 031 Funding Number: RFA AG 24 031 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Consortium for Economic Research on AD/ADRD Prevention, Treatment, and Care Coordinating Center (U54 Clinical Trial Optional) Apply for RFA AG 24 030 Funding Number: RFA AG 24 030 Agency: National Institutes of Health Category: Health Funding Amount: $2,750,000 |
| Collaborative Science to Achieve Disruptive Innovations in Dental, Oral and Craniofacial (DOC) Research (RM1 Clinical Trial Not Allowed) Apply for RFA DE 24 003 Funding Number: RFA DE 24 003 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Initiative to Maximize Research Education in Genomics: Diversity Action Plan (R25 Clinical Trials Not Allowed) Apply for PAR 22 268 Funding Number: PAR 22 268 Agency: National Institutes of Health Category: Health Funding Amount: $325,000 |
| Research Tools for Difficult to Culture Eukaryotic Pathogens (R61/R33 Clinical Trial Not Allowed) Apply for RFA AI 23 055 Funding Number: RFA AI 23 055 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Developing Salivary Components as Therapeutics for Oral Health (R01 Clinical Trial Not Allowed) Apply for RFA DE 24 004 Funding Number: RFA DE 24 004 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Developing Salivary Components as Therapeutics for Oral Health (R21 Clinical Trial Not Allowed) Apply for RFA DE 24 005 Funding Number: RFA DE 24 005 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Assay and Data Generation Centers (RM1 Clinical Trial Not Allowed) Apply for RFA MH 25 145 Funding Number: RFA MH 25 145 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| IDeA Clinical and Translational Research Network (CTR-N) Award (P50 - Clinical Trial Optional) Apply for PAR 23 241 Funding Number: PAR 23 241 Agency: National Institutes of Health Category: Health Funding Amount: $1,300,000 |
| IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional) Apply for PAR 23 257 Funding Number: PAR 23 257 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 24 043", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.